BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pawinska-wasikowska K, Wieczorek A, Balwierz W, Bukowska-strakova K, Surman M, Skoczen S. Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia. Cancers 2022;14:458. [DOI: 10.3390/cancers14020458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhou G, Wang L, Tang X, Liu S, Li T, Liu Y, Chen F, Mai H, Liu S, Wen F, Wang Y. Blinatumomab therapy for B cell acute lymphoblastic leukemia accompanied by persistent or relapsed low-level MRD prior to hematopoietic stem cell transplantation in Chinese children: a case series. Bull Natl Res Cent 2023;47:30. [DOI: 10.1186/s42269-023-00999-x] [Reference Citation Analysis]
2 Blinatumomab. Reactions Weekly 2023;1944:159-159. [DOI: 10.1007/s40278-023-33678-y] [Reference Citation Analysis]
3 Chen B, Zou Z, Zhang Q, Chen K, Zhang X, Xiao D, Li X. Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis. Front Pharmacol 2022;13:1032664. [PMID: 36703737 DOI: 10.3389/fphar.2022.1032664] [Reference Citation Analysis]
4 Kyriakidis I, Mantadakis E, Stiakaki E, Groll AH, Tragiannidis A. Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. Cancers (Basel) 2022;14:5022. [PMID: 36291806 DOI: 10.3390/cancers14205022] [Reference Citation Analysis]